Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2607 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS44470011
CAS:DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) with oral bioavailability. It enhances the release of erythropoietin (EPO) from cells and is utilized in research related to renal anemia.Formula:C21H19N3O4Color and Shape:SolidMolecular weight:377.39Pim-1 kinase inhibitor 6
CAS:Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Formula:C21H10BrCl2N3Color and Shape:SolidMolecular weight:455.13HIF-2α-IN-5
CAS:HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].Formula:C15H12F4O3S2Color and Shape:SolidMolecular weight:380.38LSD1/2-IN-4
LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07ROPA
CAS:ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.Formula:C28H32O6Purity:98%Color and Shape:SolidMolecular weight:464.55HIF-2α-IN-7
CAS:HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.Formula:C18H9F6NO2Color and Shape:SolidMolecular weight:385.26JTZ-951 HCl
CAS:JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).Formula:C17H17ClN4O4Purity:98%Color and Shape:SolidMolecular weight:376.79Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46DDO-3055
CAS:DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.Formula:C17H13ClN2O5Color and Shape:SolidMolecular weight:360.749LSD1-IN-39
CAS:LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.Formula:C25H30N2O7Color and Shape:SolidMolecular weight:470.515BET-IN-6
CAS:BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.Formula:C22H20N2O6SPurity:98%Color and Shape:SolidMolecular weight:440.47JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64Tyk2-IN-17
CAS:Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42PARP-1/HDAC-IN-1
CAS:PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.Formula:C22H18N4O4Purity:95.94%Color and Shape:SolidMolecular weight:402.4LSD1-IN-18
LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).Formula:C31H40N6O2Color and Shape:SolidMolecular weight:528.69AMPK activator 16
CAS:AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).Formula:C23H20ClNO5SColor and Shape:SolidMolecular weight:457.927TDI-015051
CAS:TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.Formula:C22H22FN5O4SColor and Shape:SolidMolecular weight:471.505(Rac)-RG108
CAS:(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.Formula:C19H14N2O4Color and Shape:SolidMolecular weight:334.326MC3138
CAS:MC3138 is a selective SIRT5 activator showing anti-tumor effects in PDAC cells.Formula:C25H25NO6Purity:99.57%Color and Shape:SolidMolecular weight:435.47Dot1L-IN-1
CAS:The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.Formula:C32H36ClN9O2SPurity:98%Color and Shape:SolidMolecular weight:646.21PF-06263276
CAS:PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63DS-9300
CAS:DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.Formula:C25H26F3N5O3Color and Shape:SolidMolecular weight:501.50Aurora A inhibitor 1
CAS:Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Formula:C25H28ClF2N5O2Color and Shape:SolidMolecular weight:503.97WIZ degrader 8
CAS:WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.Formula:C21H27N3O4Color and Shape:SolidMolecular weight:385.457AMI-408
CAS:AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.Formula:C20H13Cl2N6NaO5SColor and Shape:SolidMolecular weight:543.32MAT2A-IN-19
CAS:MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.
Formula:C23H15F5N6O3Color and Shape:SolidMolecular weight:518.396NMDAR/HDAC-IN-1
Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.Formula:C22H28N2O3Color and Shape:SolidMolecular weight:368.47MTL-CEBPA
MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.Color and Shape:SolidMAT2A-IN-16
CAS:MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.Formula:C23H17ClN6OColor and Shape:SolidMolecular weight:428.874Aurora inhibitor 1
CAS:Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).Formula:C23H25N9SPurity:98%Color and Shape:SolidMolecular weight:459.57MAT2A-IN-18
CAS:MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.Formula:C17H13ClN4OColor and Shape:SolidMolecular weight:324.764EZH2-IN-12
EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2, which has potential for studies of CNS malignancies.Formula:C23H23Cl2N3O3Color and Shape:SolidMolecular weight:460.35YEATS4 binder-1
YEATS4 binder-1(4e) is an effective and selective compound that targets the KAc recognition site within the YEATS structural domain, exhibiting a bindingFormula:C23H34N4O3Color and Shape:SolidMolecular weight:414.54Sapintoxin D
CAS:Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.Formula:C30H37NO8Color and Shape:SolidMolecular weight:539.62P300 bromodomain-IN-1
P300 bromodomain-IN-1 blocks c-Myc, induces G1/G0 arrest, apoptosis. Potent EP300 inhibitor (IC50: 49 nM).Formula:C29H31ClN4O4Color and Shape:SolidMolecular weight:535.03AR/BET protein degrader-1
CAS:AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.Formula:C43H44N6O5Molecular weight:724.85DCHC
CAS:DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.Formula:C15H8Cl2O3Color and Shape:SolidMolecular weight:307.128Bromodomain inhibitor-13
CAS:Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.43HIF-1/2α-IN-1
HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.Formula:C17H16N6O4Color and Shape:SolidMolecular weight:368.35MAT2A-IN-21
CAS:MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.
Formula:C26H20F2N4O2Color and Shape:SolidMolecular weight:458.459JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46CRV431
CAS:CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).Formula:C67H122N12O13Color and Shape:SolidMolecular weight:1303.76MAT2A-IN-20
CAS:MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.
Formula:C26H24F2N6O4Color and Shape:SolidMolecular weight:522.5035-AIQ hydrochloride
CAS:5-AIQ hydrochloride is a water-soluble PARP-1 inhibitor and serves as a vital functional group in various medications. It mitigates tissue damage associated with hepatic ischemia-reperfusion, making it valuable for research into conditions related to liver ischemia-reperfusion.Formula:C9H9ClN2OColor and Shape:SolidMolecular weight:196.634FNDR-20123
FNDR-20123: First safe, effective anti-malarial HDAC inhibitor for Plasmodium (IC50: 31 nM) & human HDACs, with nanomolar potency across several subtypes.Formula:C21H24ClN5O2Color and Shape:SolidMolecular weight:413.9JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38MAT2A-IN-17
CAS:MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.
Formula:C23H18F3N7OColor and Shape:SolidMolecular weight:465.431KDOAM-25 citrate
CAS:KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]Formula:C21H33N5O9Purity:98%Color and Shape:SolidMolecular weight:499.51HDAC6-IN-13
HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.Formula:C23H22N4OColor and Shape:SolidMolecular weight:370.45HDAC-IN-27
HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).Formula:C20H22N4O2Color and Shape:SolidMolecular weight:350.41MS8815
CAS:MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.Formula:C65H87N9O8SColor and Shape:SolidMolecular weight:1154.51NPC26
CAS:NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.Formula:C19H23N3O5S2Color and Shape:SolidMolecular weight:437.533TAF1 ligand 1
CAS:TAF1 ligand 1 is a TAF1 ligand. It can serve as a ligand for target proteins (Ligands for Target Protein for PROTAC) in the synthesis of PROTACs targeting TAF1, such as ZS3-046.Formula:C23H23N5O3Color and Shape:SolidMolecular weight:417.46FY-56
FY-56: potent, selective LSD1/KDM1A inhibitor (IC50=42nM); differentiates MOLM-13/MV4-11 cells; promising for AML research.Formula:C23H19FN2O3Color and Shape:SolidMolecular weight:390.41CFT8634
CAS:CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.Formula:C37H45F3N6O5Color and Shape:SolidMolecular weight:710.79BRD4 Inhibitor-17
BRD4 Inhibitor-17: Potent with 0.33 μM IC50; modulates gene expression, may counter arsenic toxicity.Formula:C16H16FN3O3SColor and Shape:SolidMolecular weight:349.38Pim-1 kinase inhibitor 3
CAS:Pim-1 kinase inhibitor 3 (Compound H5) is a potent inhibitor of Pim-1 kinase, demonstrating an inhibitory concentration (IC50) of 35.13 nM [1].Formula:C20H25N3O2Color and Shape:SolidMolecular weight:339.43Triciferol
CAS:Triciferol is a VDR agonist and HDAC antagonist with 1,25D-like potency, affecting gene targets and tubulin, and shows anti-cancer effects in vitro. IC50=87nM.Formula:C26H39NO4Color and Shape:SolidMolecular weight:429.591Enzomenib
CAS:Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.Formula:C33H43FN6O3Color and Shape:SolidMolecular weight:590.73HDAC6-IN-9
CAS:HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.Formula:C19H16N2O3Purity:98.84%Color and Shape:SolidMolecular weight:320.34Streptonigrin (racemate)
CAS:Streptonigrin: aminoquinone antibiotic; antitumor, antibacterial; blocks β-Catenin/Tcf, cytotoxic; alters hamster chromosomes; (-)-isomer, CAS#3930-19-6.Formula:C25H22N4O8Color and Shape:SolidMolecular weight:506.46GSK852
GSK852 is a potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor with pIC50 of 7.9.Formula:C24H26N2O4Color and Shape:SolidMolecular weight:406.47PARP1-IN-5
PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.Formula:C25H24N2O5SColor and Shape:SolidMolecular weight:464.53PAD2-IN-1 hydrochloride
PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.Formula:C25H30ClFN6O3Color and Shape:SolidMolecular weight:517RK-0080552
CAS:RK-0080552 (RK-552) is an inhibitor of the NSD2 histone methyltransferase. It demonstrates significant cytotoxicity against multiple myeloma (MM) cells harboring the t(4;14) translocation. This compound suppresses the IRF4 gene and decreases the dimethylation of histone H3 at lysine 36. RK-0080552 holds promise for research in hematologic malignancies.Formula:C12H6N6O2Color and Shape:SolidMolecular weight:266.215BRD4 Inhibitor-32
CAS:BRD4 Inhibitor-32 (example 15), a BRD4 inhibitor, is applicable in research pertaining to both acute and chronic kidney disease [1].Formula:C26H25N3O3Color and Shape:SolidMolecular weight:427.5BRD9 Degrader-2
CAS:BRD9 Degrader-2 (Compound B11), a potent BRD9 degrader (DC50≤1.25nM; Dmax≥75%), is applicable in cancer research.Formula:C40H43F3N6O4SColor and Shape:SolidMolecular weight:760.87HDAC6-IN-12
HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer researchFormula:C24H39F2N3O5Color and Shape:SolidMolecular weight:487.58Glycyl H-1152 hydrochloride
CAS:Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.Formula:C18H26Cl2N4O3SColor and Shape:SolidMolecular weight:449.39M-525
CAS:M-525, a potent first-in-class menin-MLL inhibitor, binds at 3 nM IC50 and curbs MLL leukemia cell growth & gene expression.Formula:C39H51FN6O5SPurity:98%Color and Shape:SolidMolecular weight:734.92iBRD4-BD1 diTFA
CAS:iBRD4-BD1 diTFA is a selective BRD4 bromodomain inhibitor with an IC50 value of 12 nM. It can be used for research in inflammation and oncology [1].Formula:C33H32F9N5O5Color and Shape:SolidMolecular weight:749.62CARM1-IN-3 dihydrochloride
CARM1-IN-3 dihydrochloride (17b) is a potent CARM1 inhibitor (IC50: 0.07 μM) with selectivity over CARM3 (IC50 >25 μM).Formula:C24H34Cl2N4O2Color and Shape:SolidMolecular weight:481.46NI-Pano
NI-Pano (CH-03) is a novel hypoxia-activated KDAC inhibitor capable of O2-dependent release of the compound panobinostat.Formula:C26H28N6O4Color and Shape:SolidMolecular weight:488.54HDAC3-IN-3
CAS:HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].Formula:C26H22N4O2Color and Shape:SolidMolecular weight:422.48O-Desmethyl Midostaurin
CAS:O-Desmethyl Midostaurin is the active Midostaurin metabolite via cytochrome P450 liver enzyme metabolism.Formula:C34H28N4O4Purity:98%Color and Shape:SolidMolecular weight:556.61MI-1481
CAS:MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.Formula:C29H30F3N7O2SPurity:98%Color and Shape:SolidMolecular weight:597.65STR-V-53
CAS:STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].Formula:C21H30N4O8Color and Shape:SolidMolecular weight:466.48Aurora/LIM kinase-IN-1
Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.Formula:C16H20N6OColor and Shape:SolidMolecular weight:312.37PRMT5-IN-37
CAS:PRMT5-IN-37 (compound 29), an orally active inhibitor of PRMT5, is utilized for cancer research.Formula:C21H15F4N5O2Color and Shape:SolidMolecular weight:445.37HYDAMTIQ
CAS:HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].Formula:C14H14N2O2SColor and Shape:SolidMolecular weight:274.34MMSET-IN-1
CAS:MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .Formula:C18H29N7O5Purity:98%Color and Shape:SolidMolecular weight:423.47CBP/p300-IN-16
CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM).Formula:C26H31N3O4Color and Shape:SolidMolecular weight:449.54PROTAC BRD4 Degrader-25
CAS:PROTAC BRD4 Degrader-25 (Compound 1-f), a targeted BRD4 degrader, is utilized in the study of cancer and additional diseases related to bromodomains [1].Formula:C34H30FN9O2SColor and Shape:SolidMolecular weight:647.72SRI-43265
CAS:SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].Formula:C19H20N6OColor and Shape:SolidMolecular weight:348.4PROTAC BRD4 ligand-4
CAS:PROTACBRD4 ligand-4 is a BRD4 ligand used in the synthesis of [PROTACBRD4 Degrader-37].Formula:C17H15NO4Color and Shape:SolidMolecular weight:297.31NVS-BPTF-1
CAS:NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].Formula:C26H28FN7O3SColor and Shape:SolidMolecular weight:537.61Galegine hemisulfate
CAS:Galegine hemisulfate, a guanidine derivative, aids in weight reduction in mice. It activates AMPK in 3T3-L1 adipocytes, L6 myotubes, H4IIE rat hepatoma cells, and HEK293 human renal cell lines. Galegine hemisulfate also exhibits antibacterial activity, with a minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains.Formula:C6H15N3O4SColor and Shape:SolidMolecular weight:225.27Ad-JQ1
CAS:Ad-JQ1 (Compound 16) is a Target Protein Ligand-Linker Conjugate incorporating a BRD4 ligand and a PROTAC linker capable of recruiting E3 ligase. It is utilized in the synthesis of PROTACβ-NF-JQ1.Formula:C37H47ClN6O4SColor and Shape:SolidMolecular weight:707.33NSD2-PWWP1-IN-2
CAS:NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.Formula:C29H30N4Color and Shape:SolidMolecular weight:434.575PRMT5-IN-49
CAS:PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.Formula:C19H22N2O2Color and Shape:SolidMolecular weight:310.39BRD4 Inhibitor-33
CAS:BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].Formula:C24H20N4O2Color and Shape:SolidMolecular weight:396.44CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36PRMT5-IN-50
CAS:PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.Formula:C26H23F3N6OColor and Shape:SolidMolecular weight:492.496TD034
CAS:TD034 is a selective, reversible, non-covalent inhibitor of HDAC11, with an IC50 of 5.1 nM and a Ki of 1.5 nM. It does not inhibit other HDACs or sirtuins. TD034 inhibits the desuccinylation of SHMT2 (a substrate of HDAC11) and lowers YAP1 levels by inhibiting HDAC11. TD034 is applicable for lung cancer research.Formula:C45H64N4O6Color and Shape:SolidMolecular weight:757.01BRD4-IN-7
CAS:BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.Formula:C29H24F2N4O3Color and Shape:SolidMolecular weight:514.52PARP14 inhibitor 1
CAS:PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.
Formula:C23H27FN4O3Color and Shape:SolidMolecular weight:426.484XP5
XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).Formula:C19H25N3O5SColor and Shape:SolidMolecular weight:407.48SMARCA2-IN-2
CAS:Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.Formula:C16H17N3Color and Shape:SolidMolecular weight:251.33AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32
